- New multi-purpose silicones manufacturing facility
- Investment is double-digit million euro
- Commissioning by the end of 2019
Evonik is investing a double-digit million euro amount in the construction of a new multi-purpose facility at its Geesthacht location in Northern Germany, 30 kilometers outside the city of Hamburg. The additional capacities created will be for the production of a range of silicones and silane-terminated polymers, which Evonik sells under the brand names Polymer VS and Polymer ST. The products are used in many applications including in parquet adhesives, in adhesives for wound care or encapsulation applications in electronics.
"The planned investment at the Geesthacht site has an important strategic significance by helping us to further strengthen our focus on innovative specialty chemical products," says Dietmar Schaefer, head of the Interface & Performance Business Line of Evonik.
The new plant is scheduled to go into operation at the end of 2019. Besides the increased production capacity, a facility for filling tank trucks is also being built at the site. “This will simplify the delivery and storage process for our customers and in doing so increases efficiency,” says Dr. Sabine Giessler-Blank, head of the Polymer & Construction Specialties Product Line. “The additional production capacity will also create room for us to develop new products, enabling us to increase the performance of our customers’ products and to react to future demands in the adhesives and sealants market.”
The Geesthacht site, with about 100 employees, will focus on two areas: silicone and nanotechnology. The addition- and condensation-curing silicones as well as the silane-terminated polymers are used as binders in adhesives and sealants, electronics and medical applications. Among other things, our silica-based nanomaterials serve as property-enhancing additives in fiber composites, which are used successfully in the automotive and aerospace industry.
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,250 employees, and generated sales of around €4.5 billion in 2017.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.